Timber pharmaceuticals announces first patients enrolled in phase 3 ascend clinical trial evaluating tmb-001 in congenital ichthyosis

Pivotal trial expected to enroll more than 140 patients with moderate to severe congenital ichthyosis at leading research centers in the u.s., canada, italy, france, and germany
TMBR Ratings Summary
TMBR Quant Ranking